Document Detail


Octreotide LAR treatment throughout pregnancy in an acromegalic woman.
MedLine Citation:
PMID:  11589686     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We report a 24-year-old woman with active acromegaly despite pituitary surgery and irradiation who received continuous octreotide LAR treatment for the control of GH excess throughout her pregnancy. The patient delivered a healthy girl following an uneventful pregnancy. Despite a substantial materno-fetal transfer of octreotide, postnatal development was normal with length parameters around the 50th percentile at 3 months of age. In almost all previously described cases (n = 13) octreotide was stopped after the diagnosis of pregnancy was established. No side-effects of mother or fetus have been reported. Octreotide treatment in pregnancy seems to be feasible and safe. Due to the still-limited number of reported cases, the potential benefits of octreotide treatment should be weighed carefully against its possible risks.
Authors:
M Fassnacht; B Capeller; W Arlt; T Steck; B Allolio
Related Documents :
8778426 - Successful pregnancy in a patient with hemolytic-uremic syndrome during the second trim...
12955646 - Is a black-pigmented corynebacterium species an opportunistic pathogen during pregnancy...
22393356 - A novel isolator-based system promotes viability of human embryos during laboratory pro...
18193246 - Pregnancy complicated with chronic myelogeneous leukemia (cml) successfully treated wit...
21875776 - Substituting whole blood for urine in a bedside pregnancy test.
7799976 - Multifetal pregnancy: risks and methods of reduction.
Publication Detail:
Type:  Case Reports; Journal Article; Review    
Journal Detail:
Title:  Clinical endocrinology     Volume:  55     ISSN:  0300-0664     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  2001 Sep 
Date Detail:
Created Date:  2001-10-08     Completed Date:  2001-10-25     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  England    
Other Details:
Languages:  eng     Pagination:  411-5     Citation Subset:  IM    
Affiliation:
Department of Endocrinology, University of Wuerzburg, Germany. m.fassnacht@medizin.uni-wuerzburg.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acromegaly / drug therapy*
Adenoma / drug therapy
Adult
Antineoplastic Agents, Hormonal / therapeutic use*
Delayed-Action Preparations
Female
Humans
Maternal-Fetal Exchange
Octreotide / therapeutic use*
Pituitary Neoplasms / drug therapy
Pregnancy
Pregnancy Complications, Neoplastic / drug therapy*
Pregnancy Outcome
Prenatal Care / methods*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 0/Delayed-Action Preparations; 83150-76-9/Octreotide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid c...
Next Document:  The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal Lecture.